Answers are grounded in this paper and cite their sources.
The early stages of Alzheimer’s disease (AD) consist of mild cognitive impairment (MCI) from AD and mild AD dementia. The early stages offer a crucial opportunity for intervention to reduce cognitive and functional decline. In the last decade, multiple disease-modifying and non-pharmacological interventions have been examined in randomized controlled trials (RCTs). Yet, the research is fragmented according to treatment mechanism and outcome measurement, and results are not consistent between interventions. This systematic review was conducted to summarize the evidence regarding the efficacy and safety of interventions to reduce cognitive and functional decline in early AD. An electronic search of databases, including PubMed/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Scopus, and Web of Science, was performed for RCTs published from January 2015 to September 2026 evaluating therapeutic approaches for decelerating neurocognitive decline in early AD. Adults with MCI caused by AD, prodromal AD, or mild AD dementia were included if studies described cognitive, functional, or global clinical outcomes. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement was used as a guideline in conducting the systematic review. Cochrane Risk of Bias 2 (RoB 2) tool was employed to assess risk of bias. Of the 2,712 records identified, 1,479 were screened after duplicate and automation-based removals. Following full-text assessment of 104 reports, 88 were excluded, and 16 publications (reporting 21 individual RCTs) were included in the systematic review. Lecanemab and donanemab showed slower decline of clinical endpoints in phase 3 or phase 2 studies with amyloid-related imaging abnormalities-edema (ARIA-E) in 12.6% and 24.0% of participants treated, respectively. Aducanumab achieved positive results on the primary endpoint in one out of two trials, whereas gantenerumab, crenezumab, and solanezumab showed no efficacy in slowing decline, despite amyloid clearance in certain studies. Beta-secretase inhibitors (verubecestat and lanabecestat), an anti-tau antibody (semorinemab), intranasal insulin, and oral semaglutide (two studies, 3,808 participants) demonstrated no clinical efficacy. Blarcamesine and a multinutrient approach showed beneficial outcomes; however, the bias risk was high in both cases. Supervised aerobic exercise showed reduced neuropsychiatric symptoms without consistent improvement of cognition. The bias risk in studies was low in four, some concerns in nine, and high in three studies. Monoclonal antibodies against amyloid-beta demonstrate promising but mild delay in the progression of disease in early AD. Nonetheless, the application of this treatment method is fraught with numerous dangers, including imaging alterations and possible serious complications. Data regarding the efficacy of other pharmacologic and non-pharmacologic approaches is inconclusive due to the small sample size and subject attrition. The future treatment of patients with early AD should be personalized and evidence-based. Biomarkers of amyloid-beta and tau pathology, including amyloid PET and tau PET, may facilitate patient stratification and assessment of treatment response. Large RCTs are necessary to establish the effectiveness and safety of pharmacological and non-pharmacological treatments.
No takes yet. Share an insight, caveat, or question.
Kamble et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: